A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression

Biological Psychiatry

Volumn 46, Issue 9, 1999, Pages 1301-1308

  Nelson, J Craig ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Major depression; Norepinephrine reuptake inhibitors; Serotonergic reuptake inhibitors

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DESIPRAMINE; DOSULEPIN; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LOFEPRAMINE; MAPROTILINE; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; REBOXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; ZIMELDINE;

ANXIETY; ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR BLOCKING; RELAPSE; REVIEW; SEROTONIN UPTAKE;

EID: 0033232490     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(99)00173-0     Document Type: Review

References (45)

1. Aberg A (1981): Controlled cross-over study of a 5-HT uptake inhibiting and an NA uptake inhibiting antidepressant. Acta Psychiatr Scand (suppl 290) 63:244-255.
2. Anderson I., Tomenson B. A meta-analysis of the efficacy of selective serotonin reuptake inhibitors compared to tricyclic antidepressants in depressant (abstract). Neuropsychopharmacology. 10:(suppl 2):1994;106.
3. APA Task Force Report (1985): Tricyclic antidepressants-blood level measurements and clinical outcome. Am J Psychiatry 142:155-162.
4. Ascher J.A., Cole J.O., Colin J.N., et al. Bupropion A review of its mechanism of antidepressant activity . J Clin Psychiatry. 56:1995;395-401.
5. Bolden-Watson C., Richelson E. Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci. 52:1993;1023-1029.
6. Bouchard J.M., Delaunay J., Delisle J.-P., et al. Citalopram versus maprotiline A controlled, clinical multicentre trial in depressed patients . Acta Psychiatr Scand. 76:1987;583-592.
7. Bowden C.L., Schatzberg A.F., Rosenbaum A., et al. Fluoxetine and desipramine in major depressive disorder. J Clin Psychopharmacol. 13:1993;305-310.
8. Burns R.A., Lock T., Edwards D.R.L., et al. Research report Predictors of response to amine-specific antidepressants . J Affect Disord. 35:1995;97-106.
9. Burrows G.D., Maguire K.P., Norman T.R. Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine A review . J Clin Psychiatry. 59:(suppl 14):1998;4-7.
10. Carney M.W.P., Roth M., Garside R.F. The diagnosis of depressive syndromes and prediction of ECT response. Br J Psychiatry. 111:1965;69-74.
11. Cusack B., Nelson A., Richelson E. Binding of antidepressants to human brain receptors Focus on newer generation compounds . Psychopharmacology. 114:1994;559-565.
12. deJonghe F., Ravelli D.P., Tuynmna-Qua H. A randomized, double-blind study of fluoxetine and maprotiline in the treatment of major depression. Pharmacopsychiatry. 24:1991;62-67.
13. deJonghe F., Swinkels J., Tuynmna-Qua H. Randomized double-blind study of fluvoxamine and maprotiline in treatment of depression. Pharmacopsychiatry. 24:1991;21-27.
14. Delgado P.L., Charney D.S., Price L.H., et al. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry. 47:1990;411-418.
15. Delgado P.L., Price L.H., Miller H.L., et al. Serotonin and the neurobiology of depression. Arch Gen Psychiatry. 51:1994;865-874.
16. Dubini A., Dose M., Polin V. Do noradrenaline and serotonin differentially affect social motivation and behavior? Eur Neuropsychopharmacol. 7:(suppl 1):1997;S49-S55.
17. Fabre L.F., Scharf M.B., Itil T.M. comparative efficacy and safety of nortriptyline and fluoxetine in the treatment of major depression A clinical study . J Clin Psychiatry. 52:(suppl 6):1991;62-67.
18. Feighner J.P., Robins E., Guze S.B., et al. Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry. 26:1972;57-63.
19. Frazer A. Antidepressants. J Clin Psychiatry. 58:(suppl 6):1997;9-25.
20. Guy W (1976): ECDEU Assessment Manual for Psychopharmacology. U.S. Department of Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health, pp 217-222.
21. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 23:1960;56-62.
22. Hyttel J. Citalopram-pharmacologic profile of a specific serotonergic uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry. 6:1982;277-295.
23. Joyce P.R., Paykel E.S. Predictors of drug response in depression. Arch Gen Psychiatry. 46:1989;89-99.
24. Kupfer D.J., Spiker D.G. Refractory depression Prediction of nonresponse by clinical indicators . J Clin Psychiatry. 42:1981;307-312.
25. Lundbeck H (data on file): A double-blind comparison study of citalopram and nortriptyline.
26. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 22:1959;719-748.
27. Massana J. Reboxetine versus fluoxetine an overview of efficacy and tolerability . J Clin Psychiatry. 59:(suppl 14):1998;8-10.
28. McEntee WJ, Coffey DJ, Bondareff W, et al (1995): A double-blind comparison of sertraline and nortriptyline in the treatment of depressed geriatric outpatients. Proceedings of the 148th Annual Meeting of the APA, May 20-25, Miami, FL. Washington, DC: APA Press, 126.
29. Miller H.L., Delgado P., Salomon R., et al. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Gen Psychiatry. 53:1996;117-128.
30. Montgomery S.A., Asberg M.A. New depression scale designed to be sensitive to change. Br J Psychiatry. 134:1979;382-389.
31. Montgomery S.A., Henry J., McDonald G., et al. Selective serotonin reuptake inhibitors Meta-analysis of discontinuation rates . Int Clin Psychopharmacol. 9:1994;47-53.
32. Moon C. Treatment of major depression in general practice A double-blind comparison of paroxetine and lofepramine . Br J Clin Pract. 50:1990;240-244.
33. Nelson J.C., Charney D.S. The symptoms of major depressive illness. Am J Psychiatry. 138:1981;1-12.
34. Nelson J.C., Jatlow P., Quinlan D.M., Bowers M.B. Desipramine plasma concentrations and antidepressant response. Arch Gen Psychiatry. 39:1982;1419-1422.
35. Nelson JC, Kennedy JS, Pollock BG, et al (1999): Treatment of major depression with nortriptyline or paroxetine in patients with ischemic heart disease. Am J Psychiatry 156:1024-1028.
36. Nelson J.C., Mazure C.M., Jatlow P.I. Characteristics of tricyclic refractory depression. J Clin Psychiatry. 55:1994;12-19.
37. Nelson J.C., Mazure C.M., Quinlan D.M., Jatlow P.I. Drug-responsive symptoms in melancholia. Arch Gen Psychiatry. 41:1984;663-668.
38. Poelinger W, Haber H (1989): Fluoxetine 40 mg versus maprotiline 75 mg in the treatment of outpatients with depressive disorders. Int Clin Psychopharmacol suppl 4:47-50.
39. Raskin A., Schulterbrandt J.G., Reatig N., Chase C., McKeon J.J. Differential response to chlorpromazine, imipramine, and placebo. Arch Gen Psychiatry. 23:1970;164-173.
40. Robertson M.M., Abou-Saleh M.T., Harrison D.A., et al. A double-blind controlled comparison of fluoxetine and lofepramine in major depressive illness. J Psychopharmacol. 8:1994;98-103.
41. Roose S.P., Dalack G.W., Glassman A.H., Woodring S., Walsh T., Giardina G.V. Is doxepin a safer tricyclic for the heart? J Clin Psychiatry. 52:1991;338-341.
42. Roose SP, Glassman AH, Walsh BT, Woodring S (1986): Tricyclic nonresponders, phenomenology and treatment. 143:345-348.
43. Ross S.B., Ogren S.V., Renyi A.C. (Z-)dimethylamino-1-(4-bromophenyl)-1-(3-pyridyl) propene (H 102/09), a new selective inhibitor of neuronal 5-hydroxy-trypamine uptake. Acta Pharmacol Toxicol. 39:1976;152.
44. Roth D., Mattes J., Sheehan H., Sheehan D.V. A double-blind comparison of fluovoxamine, desipramine and placebo in outpatients with depression. Prog Neuropsychopharmacol Biol Psychiatry. 14:1990;929-939.
45. Song F., Freemantle N., Sheldon T.A., et al. Selective serotonin reuptake inhibitors Meta-analysis of efficacy and acceptability . BMJ. 306:1993;683-687.